ArticleInternational journal of hepatology2012
Fungal infections: their diagnosis and treatment in transplant recipients.
Article in International journal of hepatology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 36 citations in OpenAlex.
- Molecular quantification and differentiation of Candida species in biological specimens of patients with liver cirrhosis.PloS one · 2018Trial
- Amphotericin B in the Era of New Antifungals: Where Will It Stand?Journal of fungi (Basel, Switzerland) · 2024Review
- Investigation of aspergillosis outbreak in young ducklings: Unraveling the role of hatcheries inJournal of advanced veterinary and animal research · 2023Article
- An insight into biofabrication of selenium nanostructures and their biomedical application.3 Biotech · 2023Review
- Dental and Oral Manifestations of COVID-19 Related Mucormycosis: Diagnoses, Management Strategies and Outcomes.Journal of fungi (Basel, Switzerland) · 2021Review
- Envisaging Antifungal Potential of Histatin 5: A Physiological Salivary Peptide.Journal of fungi (Basel, Switzerland) · 2021Review
- Cell Rupture and Morphogenesis Control of the Dimorphic YeastACS omega · 2021Article
- Catastrophic Brain Aspergillosis after Liver Transplantation.Case reports in transplantation · 2021Article
- Protein Interactions of the Mechanosensory Proteins Wsc2 and Wsc3 for Stress Resistance inG3 (Bethesda, Md.) · 2020Article
- Bioprospecting Sponge-Associated Microbes for Antimicrobial Compounds.Marine drugs · 2016Review
- Cutaneous infection by different Alternaria species in a liver transplant recipient.Medical mycology case reports · 2015Article
- Development of a Rapid and Low-Cost Method for the Extraction of Dermatophyte DNA.Indian journal of dermatologyArticle
- Proniosomal gel-mediated topical delivery of fluconazole: Development,Journal of advanced pharmaceutical technology & researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic fungal infections typically occur in individuals who are seriously ill with recognized risk factors such as those frequently found in transplant recipients. Unfortunately, they are often diagnosed late, when the efficacy of the available treatments is low, often less than 50%, and the cost in terms of lives lost, hospital length of stay, and total hospital costs is substantially increased. The application of antifungal therapies associated with reported efficacy rates greater than 50% are those used prophylactically. When used prophylactically, these infections are reduced in greater than 95% of the expected cases. The choice of a prophylactic agent should be based upon its ease of administration, lack of adverse effects, reduced likelihood of potential drug interactions, and its efficacy in patients with established risk factors and comorbid disease processes that include renal, hepatic, and chronic pulmonary disease. The indications for the use of currently available antifungal agents, their adverse effects, drug interactions, ease of dosing, and applicability in patients with preexisting disease states, and especially in liver transplant recipients, are presented in this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.